Last Updated: November 8, 2026

REPAGLINIDE AND METFORMIN HYDROCHLORIDE Drug Patent Profile

Name: REPAGLINIDE AND METFORMIN HYDROCHLORIDE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

When do Repaglinide And Metformin Hydrochloride patents expire, and when can generic versions of Repaglinide And Metformin Hydrochloride launch?

Repaglinide And Metformin Hydrochloride is a drug marketed by Lupin and is included in one NDA.

The generic ingredient in REPAGLINIDE AND METFORMIN HYDROCHLORIDE is metformin hydrochloride; repaglinide. There is one drug master file entry for this compound. Additional details are available on the metformin hydrochloride; repaglinide profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for REPAGLINIDE AND METFORMIN HYDROCHLORIDE?
What are the global sales for REPAGLINIDE AND METFORMIN HYDROCHLORIDE?
What is Average Wholesale Price for REPAGLINIDE AND METFORMIN HYDROCHLORIDE?

Summary for REPAGLINIDE AND METFORMIN HYDROCHLORIDE

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	22
DailyMed Link:	REPAGLINIDE AND METFORMIN HYDROCHLORIDE at DailyMed

Drug patent expirations by year for REPAGLINIDE AND METFORMIN HYDROCHLORIDE

Recent Clinical Trials for REPAGLINIDE AND METFORMIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Novartis Pharmaceuticals	Phase 1
Medicines for Malaria Venture	Phase 1
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Phase 2/Phase 3

See all REPAGLINIDE AND METFORMIN HYDROCHLORIDE clinical trials

US Patents and Regulatory Information for REPAGLINIDE AND METFORMIN HYDROCHLORIDE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	REPAGLINIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; repaglinide	TABLET;ORAL	200624-001	Jul 15, 2015		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lupin	REPAGLINIDE AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; repaglinide	TABLET;ORAL	200624-002	Jul 15, 2015		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.